Suppr超能文献

髓母细胞瘤亚组在原发和转移部位保持稳定。

Medulloblastoma subgroups remain stable across primary and metastatic compartments.

作者信息

Wang Xin, Dubuc Adrian M, Ramaswamy Vijay, Mack Stephen, Gendoo Deena M A, Remke Marc, Wu Xiaochong, Garzia Livia, Luu Betty, Cavalli Florence, Peacock John, López Borja, Skowron Patryk, Zagzag David, Lyden David, Hoffman Caitlin, Cho Yoon-Jae, Eberhart Charles, MacDonald Tobey, Li Xiao-Nan, Van Meter Timothy, Northcott Paul A, Haibe-Kains Benjamin, Hawkins Cynthia, Rutka James T, Bouffet Eric, Pfister Stefan M, Korshunov Andrey, Taylor Michael D

机构信息

Developmental and Stem Cell Biology Program, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.

出版信息

Acta Neuropathol. 2015 Mar;129(3):449-57. doi: 10.1007/s00401-015-1389-0. Epub 2015 Jan 21.

Abstract

Medulloblastoma comprises four distinct molecular variants with distinct genetics, transcriptomes, and outcomes. Subgroup affiliation has been previously shown to remain stable at the time of recurrence, which likely reflects their distinct cells of origin. However, a therapeutically relevant question that remains unanswered is subgroup stability in the metastatic compartment. We assembled a cohort of 12-paired primary-metastatic tumors collected in the MAGIC consortium, and established their molecular subgroup affiliation by performing integrative gene expression and DNA methylation analysis. Frozen tissues were collected and profiled using Affymetrix gene expression arrays and Illumina methylation arrays. Class prediction and hierarchical clustering were performed using existing published datasets. Our molecular analysis, using consensus integrative genomic data, establishes the unequivocal maintenance of molecular subgroup affiliation in metastatic medulloblastoma. We further validated these findings by interrogating a non-overlapping cohort of 19 pairs of primary-metastatic tumors from the Burdenko Neurosurgical Institute using an orthogonal technique of immunohistochemical staining. This investigation represents the largest reported primary-metastatic paired cohort profiled to date and provides a unique opportunity to evaluate subgroup-specific molecular aberrations within the metastatic compartment. Our findings further support the hypothesis that medulloblastoma subgroups arise from distinct cells of origin, which are carried forward from ontogeny to oncology.

摘要

髓母细胞瘤由四种具有不同遗传学、转录组和预后的不同分子亚型组成。先前已表明,复发时亚型归属保持稳定,这可能反映了它们不同的起源细胞。然而,一个尚未得到解答的与治疗相关的问题是转移灶中的亚型稳定性。我们收集了MAGIC联盟中12对原发-转移瘤组成的队列,并通过进行综合基因表达和DNA甲基化分析来确定它们的分子亚型归属。收集冷冻组织并使用Affymetrix基因表达阵列和Illumina甲基化阵列进行分析。使用现有的已发表数据集进行类别预测和层次聚类。我们利用一致性综合基因组数据进行的分子分析确定了转移性髓母细胞瘤分子亚型归属的明确维持。我们通过使用免疫组织化学染色的正交技术对来自布尔坚科神经外科研究所的19对原发-转移瘤的非重叠队列进行研究,进一步验证了这些发现。这项研究是迄今为止报道的最大的原发-转移配对队列分析,为评估转移灶内亚型特异性分子异常提供了独特机会。我们的发现进一步支持了髓母细胞瘤亚型起源于不同起源细胞的假说,这些细胞从个体发育延续到肿瘤学。

相似文献

1
Medulloblastoma subgroups remain stable across primary and metastatic compartments.
Acta Neuropathol. 2015 Mar;129(3):449-57. doi: 10.1007/s00401-015-1389-0. Epub 2015 Jan 21.
2
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.
Lancet Oncol. 2013 Nov;14(12):1200-7. doi: 10.1016/S1470-2045(13)70449-2. Epub 2013 Oct 17.
3
Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
Lancet Oncol. 2017 Jul;18(7):958-971. doi: 10.1016/S1470-2045(17)30243-7. Epub 2017 May 22.
4
Medulloblastoma comprises four distinct molecular variants.
J Clin Oncol. 2011 Apr 10;29(11):1408-14. doi: 10.1200/JCO.2009.27.4324. Epub 2010 Sep 7.
5
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.
J Clin Oncol. 2011 Apr 10;29(11):1424-30. doi: 10.1200/JCO.2010.28.5148. Epub 2010 Nov 22.
6
Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes.
Acta Neuropathol. 2019 Aug;138(2):309-326. doi: 10.1007/s00401-019-02020-0. Epub 2019 May 10.
7
Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations.
J Clin Oncol. 2006 Apr 20;24(12):1924-31. doi: 10.1200/JCO.2005.04.4974. Epub 2006 Mar 27.
8
Reproducibility of the NanoString 22-gene molecular subgroup assay for improved prognostic prediction of medulloblastoma.
Neuropathology. 2018 Oct;38(5):475-483. doi: 10.1111/neup.12508. Epub 2018 Aug 28.
9
Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma.
Cancer Res. 2010 Oct 15;70(20):8199-210. doi: 10.1158/0008-5472.CAN-09-4562. Epub 2010 Sep 28.
10
Active medulloblastoma enhancers reveal subgroup-specific cellular origins.
Nature. 2016 Feb 4;530(7588):57-62. doi: 10.1038/nature16546. Epub 2016 Jan 27.

引用本文的文献

1
Drivers Underlying Metastasis and Relapse in Medulloblastoma and Targeting Strategies.
Cancers (Basel). 2024 Apr 30;16(9):1752. doi: 10.3390/cancers16091752.
2
KMT2D suppresses Sonic hedgehog-driven medulloblastoma progression and metastasis.
iScience. 2023 Sep 9;26(10):107831. doi: 10.1016/j.isci.2023.107831. eCollection 2023 Oct 20.
3
The Potential Therapeutic Application of Simvastatin for Brain Complications and Mechanisms of Action.
Pharmaceuticals (Basel). 2023 Jun 22;16(7):914. doi: 10.3390/ph16070914.
4
Exploring the Molecular Complexity of Medulloblastoma: Implications for Diagnosis and Treatment.
Diagnostics (Basel). 2023 Jul 18;13(14):2398. doi: 10.3390/diagnostics13142398.
5
Clinical, Histological, and Molecular Prognostic Factors in Childhood Medulloblastoma: Where Do We Stand?
Diagnostics (Basel). 2023 May 30;13(11):1915. doi: 10.3390/diagnostics13111915.
6
Molecular characterization of sub-frontal recurrent medulloblastomas reveals potential clinical relevance.
Front Neurol. 2023 Apr 27;14:1148848. doi: 10.3389/fneur.2023.1148848. eCollection 2023.
7
Drug Resistance in Medulloblastoma Is Driven by YB-1, ABCB1 and a Seven-Gene Drug Signature.
Cancers (Basel). 2023 Feb 8;15(4):1086. doi: 10.3390/cancers15041086.
8
Pan-cancer molecular subtypes of metastasis reveal distinct and evolving transcriptional programs.
Cell Rep Med. 2023 Feb 21;4(2):100932. doi: 10.1016/j.xcrm.2023.100932. Epub 2023 Feb 1.
10
CD155 is a putative therapeutic target in medulloblastoma.
Clin Transl Oncol. 2023 Mar;25(3):696-705. doi: 10.1007/s12094-022-02975-9. Epub 2022 Oct 27.

本文引用的文献

1
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma.
Science. 2014 Jun 20;344(6190):1396-401. doi: 10.1126/science.1254257. Epub 2014 Jun 12.
2
Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing.
Nature. 2014 Jun 26;510(7506):537-41. doi: 10.1038/nature13268. Epub 2014 May 18.
3
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Science. 2014 Jan 10;343(6167):189-193. doi: 10.1126/science.1239947. Epub 2013 Dec 12.
4
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.
Lancet Oncol. 2013 Nov;14(12):1200-7. doi: 10.1016/S1470-2045(13)70449-2. Epub 2013 Oct 17.
5
High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031).
J Clin Oncol. 2013 Aug 10;31(23):2936-41. doi: 10.1200/JCO.2012.43.9984. Epub 2013 Jul 15.
6
Intertumoral and intratumoral heterogeneity as a barrier for effective treatment of medulloblastoma.
Neurosurgery. 2013 Aug;60 Suppl 1:57-63. doi: 10.1227/01.neu.0000430318.01821.6f.
8
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4009-14. doi: 10.1073/pnas.1219747110. Epub 2013 Feb 14.
9
Medulloblastomics: the end of the beginning.
Nat Rev Cancer. 2012 Dec;12(12):818-34. doi: 10.1038/nrc3410.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验